Upstream Bio, Inc.
UPB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for UPB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · UPB
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing verekitug, a product candidate for inflammatory diseases, with no approved products and a history of operating losses.
Key risk: Clinical trial delays
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for Upstream Bio, Inc..
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing verekitug, a product candidate for inflammatory diseases, with no approved products and a history of operating losses.
- Upstream Bio is a clinical-stage biopharmaceutical company developing verekitug for inflammatory diseases [sec].
- As of June 30, 2026, the company reported cash and equivalents of $79.6 million, total revenue of $0.8 million, and a net loss of $39.7 million [sec].
- The company has incurred significant losses and expects to continue incurring losses as it advances verekitug through clinical development and seeks regulatory approvals [sec_mda · as of 2026-08-11].
- Upstream Bio's operations have been funded principally through equity financings [sec_mda · as of 2026-08-11].
- The company faces risks related to clinical trial delays, regulatory approval, and the need for additional capital to fund operations [sec_mda · as of 2026-08-11].
What works
- The company has a lead product candidate, verekitug, which is being advanced through clinical development for multiple indications [sec_mda · as of 2026-08-11].
- Upstream Bio has secured equity financings to fund operations, indicating investor support for its development programs [sec_mda · as of 2026-08-11].
What to weigh
- The company has a history of operating losses and expects losses to increase as it progresses verekitug through clinical trials and regulatory processes [sec_mda · as of 2026-08-11].
- Upstream Bio will require additional funding to finance operations, and if unable to raise capital on acceptable terms, may need to delay or reduce development programs [sec_mda · as of 2026-08-11].
- Clinical development is uncertain and expensive; delays or failures in trials could harm the company's business and growth prospects [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
The company expects to continue incurring significant losses as it advances verekitug.
“We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, verekitug in multiple indications.”
SEC MD&A · August 11, 2026
The company's ability to fund development and achieve milestones is subject to risks.
“the Company's ability to advance verekitug through clinical development, and to obtain regulatory approval of and ultimately commercialize verekitug on the expected timeline, if at all; the initiation, timing, progress and results of clinical trials; the Company's ability to fund its development activities and achieve development goals”
SEC filings · February 11, 2026
The company has funded operations through equity financings.
“To date, we have funded our operations principally through equity financings.”
SEC MD&A · August 11, 2026
Risks & what to watch (3)›
Key risks
- Clinical trial delays — Delays in clinical trials could harm business and shorten exclusivity periods [sec_mda · as of 2026-08-11].
- Need for additional capital — The company will require additional funding; inability to raise capital may force program reductions [sec_mda · as of 2026-08-11].
- Regulatory approval uncertainty — Failure to demonstrate safety and efficacy could prevent regulatory approval of verekitug [sec_mda · as of 2026-08-11].
What to watch
- Progress of clinical trials for verekitug, including enrollment and data readouts [sec_mda · as of 2026-08-11].
- Regulatory submissions and interactions with health authorities regarding verekitug [sec_mda · as of 2026-08-11].
- Capital raising activities and cash runway updates [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Upstream Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Upstream Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
21.7 months
D/E 0.04 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 10 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
142
Total value held
$405.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 8,101,563 | $72.9M |
| orbimed advisors llc | 5,693,589 | $51.2M |
| vanguard capital management llc | 3,747,148 | $33.7M |
| blackrock, inc. | 3,370,689 | $30.3M |
| enavate sciences gp, llc | 2,459,703 | $22.1M |
| woodline partners lp | 1,662,962 | $15.0M |
| y-intercept (hong kong) ltd | 1,000,631 | $9.0M |
| federated hermes, inc. | 979,758 | $8.8M |
| geode capital management, llc | 950,617 | $8.6M |
| millennium management llc | 937,323 | $8.4M |
Showing top 10 of 142 institutional holders of Upstream Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 11.3%
- Days to cover
- 3.3
- Shares short
- 3,435,261
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
UPB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Upstream Bio, Inc.?
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing verekitug, a product candidate for inflammatory diseases, with no approved products and a history of operating losses.
What is Upstream Bio, Inc.'s lead drug candidate?
Upstream Bio, Inc.'s most advanced tracked candidate is verekitug (Phase 2) for Severe Asthma; Chronic Obstructive Pulmonary Disease; Chronic Rhinosinusitis With Nasal Polyps.
Who is the CEO of Upstream Bio, Inc.?
Dr. E. Rand Sutherland M.D., M.P.H. is the chief executive officer of Upstream Bio, Inc. (UPB).
Where is Upstream Bio, Inc. headquartered?
Upstream Bio, Inc. (UPB) is headquartered in Waltham, MA, United States.
What therapeutic areas does Upstream Bio, Inc. focus on?
Upstream Bio, Inc. develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.